Ceftiofur: Difference between revisions
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
Kiran Singh (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name = (6''R'',7''R'')-7-[ [(2''Z'')-2-(2-Amino-1,3-thiazol-4-yl)- 2-methoxyiminoacetyl]amino]-3-(furan-2- carbonylsulfanylmethyl)-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | | IUPAC_name = (6''R'',7''R'')-7-[ [(2''Z'')-2-(2-Amino-1,3-thiazol-4-yl)- 2-methoxyiminoacetyl]amino]-3-(furan-2- carbonylsulfanylmethyl)-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | ||
| image = Ceftiofur.png | | image =Ceftiofur.png | ||
| CAS_number = 80370-57-6 | | CAS_number = 80370-57-6 | ||
| ATC_prefix = | | ATC_prefix = | ||
| Line 23: | Line 23: | ||
| legal_status = | | legal_status = | ||
| routes_of_administration = | | routes_of_administration = | ||
__Notoc__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | |||
'''Ceftiofur''' is an [[antibiotic]] of the [[cephalosporin]] type ([[Cephalosporin#Third_generation|third generation]]), licensed for use in [[veterinary medicine]]. It was first described in 1987.<ref>{{cite journal |author=Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW |title=Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice |journal=Am. J. Vet. Res. |volume=48 |issue=7 |pages=1050–3 |year=1987 |pmid=3631686 |doi=}}</ref> It is marketed by [[pharmaceutical company]] [[Pfizer]] as '''Excede'''.<ref>{{cite web |url=http://www.pfizerah.com/index_species.asp?species=DA&country=US&lang=EN |title=Pfizer Animal ealth Dairy Information on Products and Solutions |accessdate=2007-11-20 |format= |work=}}</ref> | '''Ceftiofur''' is an [[antibiotic]] of the [[cephalosporin]] type ([[Cephalosporin#Third_generation|third generation]]), licensed for use in [[veterinary medicine]]. It was first described in 1987.<ref>{{cite journal |author=Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW |title=Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice |journal=Am. J. Vet. Res. |volume=48 |issue=7 |pages=1050–3 |year=1987 |pmid=3631686 |doi=}}</ref> It is marketed by [[pharmaceutical company]] [[Pfizer]] as '''Excede'''.<ref>{{cite web |url=http://www.pfizerah.com/index_species.asp?species=DA&country=US&lang=EN |title=Pfizer Animal ealth Dairy Information on Products and Solutions |accessdate=2007-11-20 |format= |work=}}</ref> | ||
| Line 37: | Line 37: | ||
* [http://www.excede.com/ Official website] | * [http://www.excede.com/ Official website] | ||
[[Category:Drug]] | |||
[[Category:Cephalosporin antibiotics]] | [[Category:Cephalosporin antibiotics]] | ||
[[Category:Furans]] | [[Category:Furans]] | ||
Revision as of 13:22, 10 April 2015
{{Drugbox | IUPAC_name = (6R,7R)-7-[ [(2Z)-2-(2-Amino-1,3-thiazol-4-yl)- 2-methoxyiminoacetyl]amino]-3-(furan-2- carbonylsulfanylmethyl)-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image =Ceftiofur.png | CAS_number = 80370-57-6 | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | C=19|H=17|N=5|O=7|S=3 | molecular_weight = 523.56 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
|
WikiDoc Resources for Ceftiofur |
|
Articles |
|---|
|
Most recent articles on Ceftiofur |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ceftiofur at Clinical Trials.gov Clinical Trials on Ceftiofur at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ceftiofur
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ceftiofur Discussion groups on Ceftiofur Directions to Hospitals Treating Ceftiofur Risk calculators and risk factors for Ceftiofur
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ceftiofur |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[1] It is marketed by pharmaceutical company Pfizer as Excede.[2]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[3]
References
- ↑ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). "Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice". Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686.
- ↑ "Pfizer Animal ealth Dairy Information on Products and Solutions". Retrieved 2007-11-20.
- ↑ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). "Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves". Appl. Environ. Microbiol. 72 (6): 3940–8. doi:10.1128/AEM.02770-05. PMID 16751500.